公开(公告)号：WO2006074330A2

公开(公告)日：2006-07-13

申请号：PCT/US2006/000402

申请日：2006-01-05

Applicant: ABBOTT LABORATORIES ,  ROHDE, Jeffrey, J. ,  SHUAI, Qi ,  LINK, James, T. ,  PATEL, Jyoti, R. ,  DINGES, Jurgen ,  SORENSEN, Bryan, K. ,  YONG, Hong

Inventor： ROHDE, Jeffrey, J. ,  SHUAI, Qi ,  LINK, James, T. ,  PATEL, Jyoti, R. ,  DINGES, Jurgen ,  SORENSEN, Bryan, K. ,  YONG, Hong

IPC: C07C233/63 ,  C07D213/56 ,  C07D231/12 ,  C07D261/08 ,  C07D333/24 ,  A61K31/165 ,  A61K31/4409 ,  A61K31/381 ,  A61K31/415 ,  A61K31/42 ,  A61P3/04 ,  A61P3/10

CPC classification number: C07D207/277 ,  C07C233/11 ,  C07C233/52 ,  C07C233/58 ,  C07C233/63 ,  C07C237/24 ,  C07C2601/02 ,  C07C2601/04 ,  C07C2601/08 ,  C07C2601/14 ,  C07C2603/74 ,  C07D211/78 ,  C07D213/56 ,  C07D231/12 ,  C07D261/08 ,  C07D333/24

Abstract: The present invention relates to compounds that are inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for the treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome and other diseases and conditions that are mediated by excessive glucocorticoid action.

Abstract translation: 本发明涉及作为11-β-羟基类固醇脱氢酶1型酶的抑制剂的化合物。 本发明还涉及11-β-羟基类固醇脱氢酶1型抑制剂用于治疗非胰岛素依赖性2型糖尿病，胰岛素抵抗，肥胖症，脂质障碍，代谢综合征和其他介导的疾病和病症的用途 由过度的糖皮质激素作用。

公开(公告)号：WO2004083207A1

公开(公告)日：2004-09-30

申请号：PCT/US2003/007689

申请日：2003-03-12

Applicant: ABBOTT LABORATORIES

Inventor： ANDERSON, David ,  BEUTEL, Bruce ,  BOSSE, Todd, D. ,  CLARK, Richard ,  COOPER, Curt ,  DANDLIKER, Peter ,  DAVID, Caroline ,  GU, Yu-Gui ,  HANSEN, Todd, Matthew ,  HINMAN, Mira ,  KALVIN, Douglas ,  LARSON, Daniel, P. ,  LYNCH, Linda ,  MA, Zhenkun ,  MOTTER, Christopher ,  PALAZZO, Fabio ,  ROSENBERG, Teresa ,  REHM, Tamara ,  SANDERS, William ,  TUFANO, Michael ,  WAGNER, Rolf ,  WEITZBERG, Moshe ,  YONG, Hong ,  ZHANG, Tianyuan

IPC: C07D471/04

CPC classification number: C07D471/04

Abstract: Antibacterials having formula (I), and salts, prodrugs, and salts of prodrugs thereof, processes for making the compounds and intermediates used in the processes, compositions containing the compounds, and methods of prophylaxis and treatment of bacterial infections using the compounds are disclosed.

Abstract translation: 公开了具有式（I）的抗菌剂及其前体药物的盐，前药和盐，用于制备本方法中使用的化合物和中间体的方法，含该化合物的组合物，以及使用该化合物预防和治疗细菌感染的方法。

公开(公告)号：WO2004026822A2

公开(公告)日：2004-04-01

申请号：PCT/US2003/029018

申请日：2003-09-15

Applicant: ABBOTT LABORATORIES

Inventor： MADAR, David ,  PEI, Zhonghua ,  PIREH, Daisy ,  DJURIC, Stevan, W. ,  WIEDEMAN, Paul, E. ,  YONG, Hong ,  FEENSTRA, Melissa, J. ,  KOPECKA, Hana ,  LI, Xiaofeng ,  LONGENECKER, Kenton ,  SHAM, Hing, L. ,  STEWART, Kent, D. ,  SZCZEPANKIEWICZ, Bruce, G.

IPC: C07D207/00

CPC classification number: C07D207/27 ,  C07D207/16 ,  C07D401/06 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D405/12 ,  C07D417/12

Abstract: The present invention relates to compounds which inhibit dipeptidyl peptidase IV (DPP-IV) and are useful for the prevention or treatment of diabetes, especially type II diabetes, as well as hyperglycemia, Syndrome X, hyperinsulinemia, obesity, atherosclerosis, and various immunomodulatory diseases.

Abstract translation: 本发明涉及抑制二肽基肽酶IV（DPP-IV）的化合物，其可用于预防或治疗糖尿病，特别是II型糖尿病，以及高血糖症，X综合征，高胰岛素血症，肥胖症，动脉粥样硬化和各种免疫调节疾病 。

公开(公告)号：WO2003093289A1

公开(公告)日：2003-11-13

申请号：PCT/US2003/012971

申请日：2003-04-25

Applicant: ABBOTT LABORATORIES

Inventor： GU, Yugui ,  MA, Zhenkun ,  YONG, Hong

IPC: C07H17/08

CPC classification number: C07H17/08

Abstract: Antibacterial compounds having formula (I) and formula (II), and salts, prodrugs, and salts of prodrugs thereof, processes for making the compounds and intermediates used in the processes, compositions containing the compounds, and methods for prophylaxis or treatment of bacterial infections using the compounds are disclosed.

Abstract translation: 具有式（I）和式（II）的抗菌化合物及其前体药物的盐，前药和盐，用于制备本方法中使用的化合物和中间体的方法，含有该化合物的组合物，以及预防或治疗细菌感染的方法 公开了使用该化合物。

公开(公告)号：WO2003090760A1

公开(公告)日：2003-11-06

申请号：PCT/US2003/012461

申请日：2003-04-23

Applicant: ABBOTT LABORATORIES

Inventor： MA, Zhenkun ,  DJURIC, Stevan ,  FLORJANCIC, Alan, S. ,  YONG, Hong ,  GU, YUGUI

IPC: A61K31/7048

CPC classification number: C07H17/08

Abstract: Antibacterial compounds having formula (I) and formula (II), and salts, prodrugs, and salts of prodrugs thereof, processes for making the compounds and intermediates employed in the processes, compositions containing the compounds, and methods for prophylaxis or treatment of bacterial infections in a fish or a mammal using the compounds are disclosed.

Abstract translation: 具有式（I）和式（II）的抗菌化合物及其前体药物的盐，前药和盐，用于制备本方法中使用的化合物和中间体的方法，含有该化合物的组合物，以及预防或治疗细菌感染的方法 公开了使用该化合物的鱼或哺乳动物。

公开(公告)号：WO2003068791A2

公开(公告)日：2003-08-21

申请号：PCT/US2003/004130

申请日：2003-02-11

Applicant: ABBOTT LABORATORIES

Inventor： MA, Zhenkun ,  KEYES, Robert ,  DJURIC, Stevan ,  YONG, Hong

IPC: C07H17/00

CPC classification number: C07H17/08

Abstract: Compounds having activity against methicillin-resistant staphylococcus aureus (MRSA), the compounds having formula (I), and salts, prodrugs, and salts of prodrugs thereof, processes for making the compounds and intermediates used in the processes, compositions containing the compounds, and methods for prophylaxis and treatment of MRSA infections using the compounds are disclosed.

Abstract translation: 具有抗甲氧西林抗性金黄色葡萄球菌（MRSA）活性的化合物，具有式（I）的化合物及其前体药物的盐，前体药物和盐，用于制备该方法中使用的化合物和中间体的方法，包含该化合物的组合物和 公开了使用该化合物预防和治疗MRSA感染的方法。

公开(公告)号：WO2009026422A3

公开(公告)日：2009-02-26

申请号：PCT/US2008/073830

申请日：2008-08-21

Applicant: ABBOTT LABORATORIES ,  BITNER, R., Scott ,  BROWMAN, Kaitlin, E ,  BRUNE, Michael, E ,  CHEN, Yixian ,  DINGES, Jurgen ,  DRESCHER, Karla ,  JACOBSON, Peer ,  JAE, Hwan-soo ,  KURUKULASURIYA, Ravi ,  LINK, James, T. ,  MADAR, David, J. ,  PATEL, Jyoti, R. ,  PLIUSHCHEV, Marina, A. ,  ROHDE, Jeffrey, J. ,  RUETER, Lynne, E. ,  SHUAI, Qi ,  SORENSEN, Bryan, K. ,  WANG, Jiahong ,  WICKE, Karsten, M. ,  WINN, Martin ,  WODKA, Dariusz ,  YEH, Vince ,  YONG, Hong

Inventor： BITNER, R., Scott ,  BROWMAN, Kaitlin, E ,  BRUNE, Michael, E ,  CHEN, Yixian ,  DINGES, Jurgen ,  DRESCHER, Karla ,  JACOBSON, Peer ,  JAE, Hwan-soo ,  KURUKULASURIYA, Ravi ,  LINK, James, T. ,  MADAR, David, J. ,  PATEL, Jyoti, R. ,  PLIUSHCHEV, Marina, A. ,  ROHDE, Jeffrey, J. ,  RUETER, Lynne, E. ,  SHUAI, Qi ,  SORENSEN, Bryan, K. ,  WANG, Jiahong ,  WICKE, Karsten, M. ,  WINN, Martin ,  WODKA, Dariusz ,  YEH, Vince ,  YONG, Hong

IPC: A61K31/495 ,  A61K31/445 ,  C07C233/23 ,  C07D471/02

Abstract: A method for treating a patient suffering from disorders and deficits of the central nervous system associated with diabetes, associated with aging and neurodegeneration, comprising attention deficit disorder in general, attention deficit hyperactivity disorder (ADHD), Alzheimer's disease (AD), mild cognitive impairment, senile dementia, AIDS dementia, neurodegeneration, depression, and schizophrenia, comprising administering to a patient in need of such treatment an effective amount of a selective inhibitor of the 11-β-hydroxysteroid dehydrogenase Type 1 enzyme activity.

公开(公告)号：WO2007027651A3

公开(公告)日：2007-03-08

申请号：PCT/US2006/033620

申请日：2006-08-25

Applicant: ABBOTT LABORATORIES ,  PEI, Zhonghua ,  VON GELDERN, Thomas ,  MADAR, David, J. ,  LI, Xiaofeng ,  BASHA, Fatima ,  YONG, Hong ,  LONGENECKER, Kenton, L. ,  BACKES, Bradley, J. ,  JUDD, Andrew, S. ,  MULHERN, Mathew, M. ,  STEWART, Kent, D.

Inventor： PEI, Zhonghua ,  VON GELDERN, Thomas ,  MADAR, David, J. ,  LI, Xiaofeng ,  BASHA, Fatima ,  YONG, Hong ,  LONGENECKER, Kenton, L. ,  BACKES, Bradley, J. ,  JUDD, Andrew, S. ,  MULHERN, Mathew, M. ,  STEWART, Kent, D.

IPC: C07C211/40 ,  C07C211/54 ,  C07C211/62 ,  C07D213/38 ,  C07D213/68 ,  C07D317/64 ,  C07D487/04 ,  A61K31/137

Abstract: The present invention relates to compounds, which inhibit dipeptidyl peptidase IV (DPP-IV) and are useful for the prevention or treatment of diabetes, especially type II diabetes, as well as hyperglycemia, metabolic syndrome , hyperinsulinemia, obesity, atherosclerosis, various immunomodulatory diseases, and other diseases.

公开(公告)号：WO2006074244A2

公开(公告)日：2006-07-13

申请号：PCT/US2006/000210

申请日：2006-01-05

Applicant: ABBOTT LABORATORIES ,  PATEL, Jyoti, R. ,  SHUAI, Qi ,  LINK, James, T. ,  ROHDE, Jeffrey, J. ,  DINGES, Jurgen ,  SORENSEN, Bryan, K. ,  WINN, Martin ,  YONG, Hong ,  YEH, Vince, S.

Inventor： PATEL, Jyoti, R. ,  SHUAI, Qi ,  LINK, James, T. ,  ROHDE, Jeffrey, J. ,  DINGES, Jurgen ,  SORENSEN, Bryan, K. ,  WINN, Martin ,  YONG, Hong ,  YEH, Vince, S.

IPC: C07C235/14 ,  C07C317/16 ,  C07C323/41 ,  C07D257/04 ,  C07D233/54 ,  C07D261/08 ,  C07D213/64 ,  C07D207/48 ,  A61K31/4402 ,  A61P3/10

CPC classification number: C07C233/23 ,  C07C235/14 ,  C07C237/24 ,  C07C255/31 ,  C07C255/47 ,  C07C259/16 ,  C07C311/08 ,  C07C311/29 ,  C07C311/46 ,  C07C311/51 ,  C07C317/22 ,  C07C317/30 ,  C07C317/44 ,  C07C323/41 ,  C07C323/60 ,  C07C2601/04 ,  C07C2601/14 ,  C07C2601/18 ,  C07C2602/08 ,  C07C2602/10 ,  C07C2603/74 ,  C07D207/48 ,  C07D213/64 ,  C07D233/64 ,  C07D257/04 ,  C07D261/08

Abstract: The present invention relates to compounds which are inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for the treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome and other diseases and conditions that are mediated by excessive glucocorticoid action.

Abstract translation: 本发明涉及作为11-β-羟基类固醇脱氢酶1型酶抑制剂的化合物。 本发明还涉及11-β-羟基类固醇脱氢酶1型抑制剂用于治疗非胰岛素依赖性2型糖尿病，胰岛素抵抗，肥胖症，脂质障碍，代谢综合征和其他介导的疾病和病症的用途 由过度的糖皮质激素作用。

公开(公告)号：WO2003068791A3

公开(公告)日：2003-08-21

申请号：PCT/US2003/004130

申请日：2003-02-11

Applicant: ABBOTT LABORATORIES

Inventor： MA, Zhenkun ,  KEYES, Robert ,  DJURIC, Stevan ,  YONG, Hong

IPC: C07H17/08

Abstract: Compounds having activity against methicillin-resistant staphylococcus aureus (MRSA), the compounds having formula (I), and salts, prodrugs, and salts of prodrugs thereof, processes for making the compounds and intermediates used in the processes, compositions containing the compounds, and methods for prophylaxis and treatment of MRSA infections using the compounds are disclosed.